Related Experiment Video
Updated: Dec 24, 2025
Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs
Published on: January 27, 2023
Translational strategies in drug development for knee osteoarthritis
Kyra J Cowan1, Kerstin Kleinschmidt-Dörr1, Anne Gigout1
1Merck KGaA, Darmstadt, Germany.
Abstract:
Osteoarthritis (OA) is a common disease worldwide with large unmet medical needs. To bring innovative treatments to OA patients, we at Merck have implemented a comprehensive strategy for drug candidate evaluation. We have a clear framework for decision-making in our preclinical pipeline, to design our clinical proof-of-concept trials for OA patients. We have qualified our strategy to define and refine dose and dosing regimen, for treatments administered either systemically or intra-articularly (IA). We do this through preclinical in vitro and in vivo studies, and by back-translating results from clinical studies in OA patients.
Insights
Merck employs a rigorous strategy to evaluate drug candidates for osteoarthritis (OA), a widespread disease. This approach guides the design of clinical trials to accelerate the development of novel OA treatments.
Area of Science:
- Rheumatology and Drug Development
- Biomedical Research
- Clinical Trial Design
Background:
- Osteoarthritis (OA) is a prevalent global degenerative joint disease with significant unmet medical needs.
- The development of effective OA treatments requires robust preclinical and clinical evaluation strategies.
Purpose of the Study:
- To outline Merck's comprehensive strategy for evaluating drug candidates for osteoarthritis.
- To detail the framework used for decision-making in the preclinical pipeline and the design of clinical proof-of-concept trials for OA patients.
Main Methods:
- Implementation of a decision-making framework for preclinical drug candidate evaluation.
- Qualification of a strategy to define optimal dose and dosing regimens for systemic and intra-articular (IA) administration.
- Integration of in vitro, in vivo preclinical studies, and back-translation of clinical data from OA patients.
Main Results:
- A structured approach for advancing OA drug candidates from preclinical to clinical stages.
- Validated methods for dose and regimen determination in OA drug development.
- A data-driven process combining preclinical and clinical insights.
Conclusions:
- Merck's comprehensive strategy provides a clear framework for advancing innovative osteoarthritis treatments.
- The integrated approach ensures rigorous evaluation and optimization of drug candidates for OA patients.
- This systematic methodology supports the efficient design of clinical trials and the refinement of dosing strategies.
